<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28225974</article-id>
      <article-id pub-id-type="pmc">5312196</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20174602</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Syndrome in Question</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Do you know this syndrome? Hand-foot syndrome<xref ref-type="fn" rid="fn1">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Braghiroli</surname>
            <given-names>Cintia Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ieiri</surname>
            <given-names>Rodrigo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ocanha</surname>
            <given-names>Juliana Polizel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paschoalini</surname>
            <given-names>Rafael Bispo</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miot</surname>
            <given-names>H&#xE9;lio Amante</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Department of Dermatology and Radiotherapy, Medical
School of Botucatu - Universidade Estadual Paulista "J&#xFA;lio de Mesquita Filho"
(Unesp) - Botucatu (SP), Brazil</aff>
      <aff id="aff2"><label>2</label>Department of Pathology, Medical School of Botucatu -
Universidade Estadual Paulista "J&#xFA;lio de Mesquita Filho" (Unesp) - Botucatu
(SP), Brazil</aff>
      <author-notes>
        <corresp id="c1">Mailing address: H&#xE9;lio Amante Miot, Departamento de
Dermatologia e Radioterapia, Faculdade de Medicina de Botucatu - Unesp SN,
18618-000 Botucatu, SP, Brazil. E-mail: <email>heliomiot@fmb.unesp.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Feb</season>
        <year>2017</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2017</year>
      </pub-date>
      <volume>92</volume>
      <issue>1</issue>
      <fpage>131</fpage>
      <lpage>133</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>4</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>7</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2017 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2017</copyright-year>
        <copyright-holder>Anais Brasileiros de Dermatologia</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Hand-foot syndrome is a common cutaneous adverse effect associated with certain
systemic chemotherapy drugs. It is characterized by erythema, edema, and burning
sensation, especially over palmoplantar surfaces. We report the case of an
elderly patient undergoing chemotherapy after a breast cancer surgery who
developed symptoms two months after the start of the regimen. There are no
studies that explore specific therapies. Suggestive therapy include reducing
agent dosage, increasing the interval between cycles, or even stopping
chemotherapy. Emollients, analgesics, and cold packs are described as effective.
After alopecia and mucositis, hand-foot syndrome is the most common adverse
dermatologic reaction to chemotherapeutic agents.</p>
      </abstract>
      <kwd-group>
        <kwd>Adjuvant chemotherapy</kwd>
        <kwd>Chemotherapy</kwd>
        <kwd>Drug eruption</kwd>
        <kwd>Hand-foot syndrome</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>CASE REPORT</title>
      <p>We report a 73-year-old woman under post-surgical chemotherapy (breast ductal
carcinoma) who presented with transudation and pain on the lower limbs 20 days after
the first cycle with doxorubicin and cyclophosphamide and no improvement with
furosemide.</p>
      <p>Due to treatment failure after four cycles of adjuvant regimen, the patient was
started on herceptin and paclitaxel. From the 45<sup>th</sup> day of this new
regimen, we observed the development of an edema and considerable erythema on the
hands, wrists, legs, and feet. We also observed desquamation, ulceration,
vesicopustules, and intense burning sensation. Little improvement was observed after
analgesia, topical corticosteroids and cephalexin (<xref ref-type="fig" rid="f1">Figures 1</xref> and <xref ref-type="fig" rid="f2">2</xref>).</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Erythema and acral edema on the lower limbs, with flaking and areas of
ulceration</p>
          </caption>
          <graphic xlink:href="abd-92-01-0131-gf01"/>
        </fig>
      </p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Detail of scaly erythematous lesions of the posterior region of the
ankles with areas of ulceration and vesicopustules</p>
          </caption>
          <graphic xlink:href="abd-92-01-0131-gf02"/>
        </fig>
      </p>
      <p>Laboratory tests were normal. Histopathological examination showed areas of epidermal
necrosis with small clefts, keratinocyte apoptosis, parakeratosis foci, and basal
vacuolar degeneration with extensive involvement of the acrosyringium without
squamous syringometaplasia.</p>
      <p>We opted for hospitalization, suspension of chemotherapy, and administration of
opioids, prednisone (0.5 mg/kg), potassium permanganate compresses, and application
of occlusive dressing with fludroxycortide. The patient was discharged five days
later with significant improvement in pain and lesions.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Hand-foot syndrome (HFS) - or palmar-plantar erythrodysesthesia, acral erythema, or
Burgdorf reaction - is an adverse event of many chemotherapeutic agents, especially
liposomal doxorubicin, capecitabine, 5-fluorouracil, cytarabine, docetaxel,
sorafenib, sunitinib, cyclophosphamide, etoposide, vinorelbine, methotrexate,
hydroxyurea, tegafur, mercaptopurine, and paclitaxel.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup></p>
      <p>After alopecia and mucositis, HFS is the most common adverse dermatologic reaction to
chemotherapy, with an incidence of 3%-64%. The highest incidences occur with
doxorubicin (40%-50%) and capecitabine (50%-60%). The risk of HFS seems to be
dose-dependent: formulations that prolong the serum level or that concentrate the
drug at the affected sites have the highest association rates.<sup><xref rid="r1" ref-type="bibr">1</xref></sup></p>
      <p>The pathogenesis of HFS is not known. It is believed to be a toxic reaction due to
the local accumulation of the drug with consequent degeneration and necrosis of the
sweat glands. That is because its microscopic features resemble squamous eccrine
syringometaplasia and neutrophilic eccrine hidradenitis patterns.<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref></sup></p>
      <p>HFS presents with prodromal dysesthesia and palmar-plantar tingling. Within days, the
reaction progresses to burning pain, well-defined edema and erythema with a tendency
to symmetry and flaking, and limitation of daily activities. Extreme cases involve
ulceration and blisters, palmoplantar keratoderma, nail dystrophy, inflammation of
actinic keratoses, and may affect the folds of the skin (axillary, inguinal,
perineal, and inframammary).<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r6" ref-type="bibr">6</xref></sup></p>
      <p>Different classifications grade the severity of HFS. The two most commonly used
criteria are provided by the World Health Organization and by the National Cancer
Institute (<xref ref-type="table" rid="t1">Chart 1</xref>).<sup><xref rid="r7" ref-type="bibr">7</xref></sup></p>
      <table-wrap id="t1" orientation="portrait" position="float">
        <label>Chart 1</label>
        <caption>
          <p>Clinical description of severity for hand-foot syndrome according to
NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for
Adverse Events) and WHO (World Health Organization) and associated
histologic findings</p>
        </caption>
        <table frame="box" rules="groups">
          <colgroup span="1">
            <col width="4%" span="1"/>
            <col width="32%" span="1"/>
            <col width="32%" span="1"/>
            <col width="32%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Grade</th>
              <th align="left" rowspan="1" colspan="1">NCI-CTCAE (version 4.03)</th>
              <th align="left" rowspan="1" colspan="1">WHO</th>
              <th align="left" rowspan="1" colspan="1">Histological findings</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">minimal skin changes OR dermatitis (e.g.
erythema,<break/> edema, or hyperkeratosis) NO pain</td>
              <td align="left" rowspan="1" colspan="1">Dysesthesia/paresthesia, tingling in hands and<break/>
feet</td>
              <td align="left" rowspan="1" colspan="1">Dilated vessels in the<break/> superficial
dermal<break/> plexus</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">Cutaneous lesions (e.g. flaking, blistering,
bleeding,<break/> swelling, and hyperkeratosis) WITH pain,
but<break/> with minimum limitation</td>
              <td align="left" rowspan="1" colspan="1">Discomfort when holding objects and walking,<break/>
painless swelling, or erythema</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">3</td>
              <td align="left" rowspan="1" colspan="1">Ulcerative dermatitis or serious painful
cutaneous<break/> lesions (e.g. flaking, blistering, bleeding,
swelling,<break/> and hyperkeratosis) interfering with function
and<break/> self-care</td>
              <td align="left" rowspan="1" colspan="1">Painful erythema and swelling of the palms and<break/>
soles; erythema and periungual swelling</td>
              <td align="left" rowspan="1" colspan="1">Isolated keratinocytes<break/> necrosis in the<break/>
outer layers of the<break/> epidermis</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">4</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Desquamation, ulceration, blistering, and
severe<break/> pain</td>
              <td align="left" rowspan="1" colspan="1">Complete epidermal<break/> necrosis</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>There are no longitudinal studies that explore specific treatments. Suggestive
therapy include reducing chemotherapy dosage, increasing the interval between
cycles, or even stopping chemotherapy, which would lead to remission of the picture
in up to two weeks. Dressings, rigorous analgesia, emollients, cold compresses, and
potent topical corticosteroids associated with emollients or systemic
corticosteroids are reported as efficient. Cooling of the hands and feet and use of
emollients and antiperspirants (aluminum chloride hydroxide) during infusions can
prevent the reaction. Oral pyridoxine showed no preventive efficacy in
HFS.<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r8" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>With an aging population and greater access to health care and oncological diagnosis,
cutaneous reactions to chemotherapy should become more frequent. Prevention,
identification, and early intervention is essential for clinicians in cases of
HFS.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflict of Interest: None</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Study conducted at the Department of Dermatology and Radiotherapy, Medical School
of Botucatu - Universidade Estadual Paulista "J&#xFA;lio de Mesquita Filho"
(Unesp) - Botucatu (SP), Brazil</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Webster-Gandy</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>How</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Harrold</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Palmar-plantar erythrodysesthesia (PPE): a literature review with
commentary on experience in a cancer centre</article-title>
          <source>Eur J Oncol Nurs</source>
          <year>2007</year>
          <volume>11</volume>
          <fpage>238</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="pmid">17350337</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Gorcey</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>McLellan</surname>
              <given-names>BN</given-names>
            </name>
          </person-group>
          <article-title>Chemotherapy-induced hand-foot syndrome and nail changes: a
review of clinical presentation, etiology, pathogenesis, and
management</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2014</year>
          <volume>71</volume>
          <fpage>787</fpage>
          <lpage>794</lpage>
          <pub-id pub-id-type="pmid">24795111</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martschick</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sehouli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Patzelt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Richter</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jacobi</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Oskay-Ozcelik</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The pathogenetic mechanism of anthracycline-induced
palmar-plantar erythrodysesthesia</article-title>
          <source>Anticancer Res</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>2307</fpage>
          <lpage>2313</lpage>
          <pub-id pub-id-type="pmid">19528496</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suwattee</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Warshaw</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Sunitinib: a cause of bullous palmoplantar erythrodysesthesia,
periungual erythema, and mucositis</article-title>
          <source>Arch Dermatol</source>
          <year>2008</year>
          <volume>144</volume>
          <fpage>123</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="pmid">18209189</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sapp</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>DeSimone</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Palmar-plantar erythrodysesthesia associated with scrotal and
penile involvement with capecitabine</article-title>
          <source>Clin Colorectal Cancer</source>
          <year>2007</year>
          <volume>6</volume>
          <fpage>382</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="pmid">17311704</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siqueira</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Miot</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
          <article-title>Inflammation of multiple seborrheic keratoses induced by
chemotherapy with gemcitabine</article-title>
          <source>An Bras Dermatol</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>410</fpage>
          <lpage>413</lpage>
          <pub-id pub-id-type="pmid">19851675</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanches Junior</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Moure</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Criado</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Adverse mucocutaneous reactions to chemotherapeutic agentes: part
I</article-title>
          <source>An Bras Dermatol</source>
          <year>2010</year>
          <volume>85</volume>
          <fpage>425</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="pmid">20944902</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Templeton</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Ribi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Surber</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hsu Schmitz</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Beyeler</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevention of palmar-plantar erythrodysesthesia with an
antiperspirant in breast cancer patients treated with pegylated liposomal
doxorubicin (SAKK 92/08)</article-title>
          <source>Breast</source>
          <year>2014</year>
          <volume>23</volume>
          <fpage>244</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="pmid">24656636</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lademann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Martschick</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kluschke</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Richter</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fluhr</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Patzelt</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficient prevention strategy against the development of a
palmar-plantar erythrodysesthesia during chemotherapy</article-title>
          <source>Skin Pharmacol Physiol</source>
          <year>2014</year>
          <volume>27</volume>
          <fpage>66</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">23969763</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jo</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Myung</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Prophylactic and therapeutic efficacy of pyridoxine supplements
in the management of hand-foot syndrome during chemotherapy: a
meta-analysis</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2015</year>
          <volume>40</volume>
          <fpage>260</fpage>
          <lpage>270</lpage>
          <pub-id pub-id-type="pmid">25557587</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
